Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

(124)I-cMAb U36

Known as: 124I-cMAb U36 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Monoclonal AntibodiescMAb U36

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients
Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-based therapy. For this purpose, the long… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2008
2008
Targeting CD44v6 Expressed in Head and Neck Squamous Cell Carcinoma: Preclinical Characterization of an 111In-Labeled Monoclonal Antibody
In patients with head and neck squamous cell carcinoma (HNSCC) radioimmunodiagnosis could offer a more specific and sensitive… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 6
  • figure 5
2005
2005
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma
PurposeThe purpose of this study was to analyse the properties of the astatinated chimeric MAb (cMAb) U36 as a conjugate to… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
2005
2005
Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer
Data from an ongoing clinical radioimmunoscintigraphy trial indicate that99mTc-labeled monoclonal antibody (mAb) E48 is highly… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Highly Cited
2004
Highly Cited
2004
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy
PurposeMonoclonal antibodies (MAbs) labelled with 124I are an attractive option for quantitative imaging with positron emission… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
2003
2003
Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods.
We have evaluated the applicability of the [(4-isothiocyanatobenzylammonio)undecahydro-closo-dodecaborate (1-)] (DABI) linker… Expand
2002
2002
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose…
PURPOSE In an earlier Phase I radioimmunotherapy (RIT) study with rhenium-186-labeled chimeric monoclonal antibody (cMAb) U36 in… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Highly Cited
2000
Highly Cited
2000
Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
UNLABELLED A phase I therapy study was conducted to determine the safety, maximum tolerated dose (MTD), pharmacokinetics… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 4
Highly Cited
2000
Highly Cited
2000
Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy
Coupling of photosensitizers to tumor‐selective monoclonal antibodies ( MAbs ) is an attractive option for improving the… Expand
1997
1997
Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice
Abstract At our laboratory we are currently evaluating the suitability of mouse/human chimeric monoclonal antibodies (cmAb) for… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE